Discovery and biological evaluation of a potent small molecule CRM1 inhibitor for its selective ablation of extranodal NK/T cell lymphoma

  1. He Liu
  2. Meisuo Liu
  3. Xibao Tian
  4. Haina Wang
  5. Jiujiao Gao
  6. Hanrui Li
  7. Zhehuan Zhao
  8. Yu Liu
  9. Caigang Liu  Is a corresponding author
  10. Xuan Chen
  11. Yongliang Yang  Is a corresponding author
  1. Dalian University of Technology, China
  2. Shengjing Hospital of China Medical University, China

Abstract

Background: The overactivation of NF-κB signaling is a key hallmark for the pathogenesis of extranodal natural killer/T cell lymphoma (ENKTL), a very aggressive subtype of non-Hodgkin's lymphoma yet with rather limited control strategies. Previously, we found that the dysregulated exportin-1 (also known as CRM1) is mainly responsible for tumor cells to evade apoptosis and promote tumor-associated pathways such as NF-κB signaling.

Methods: Herein we reported the discovery and biological evaluation of a potent small molecule CRM1 inhibitor, LFS-1107. We validated that CRM1 is a major cellular target of LFS-1107 by biolayer interferometry assay (BLI) and the knockdown of CRM1 conferred tumor cells with resistance to LFS-1107.

Results: We found that LFS-1107 can strongly suppresses the growth of ENKTL cells at low-range nanomolar concentration yet with minimal effects on human platelets and healthy peripheral blood mononuclear cells. Treatment of ENKTL cells with LFS-1107 resulted in the nuclear retention of IkBa and consequent strong suppression of NF-kB transcriptional activities, NF-kB target genes downregulation and attenuated tumor cell growth and proliferation. Furthermore, LFS-1107 exhibited potent activities when administered to immunodeficient mice engrafted with human ENKTL cells.

Conclusions: Therefore, LFS-1107 holds great promise for the treatment of ENKTL and may warrant translation for use in clinical trials.

Funding: Yang's laboratory was supported by the National Natural Science Foundation of China (Grant: 81874301), the Fundamental Research Funds for Central University (Grant: DUT22YG122) and the Key Research project of 'be Recruited and be in Command' in Liaoning Province (Personal Target Discovery for Metabolic Diseases).

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting file. Source data files have been provided for Figures 1, 2 and 3 as well as their associated Supplemental Figures.

Article and author information

Author details

  1. He Liu

    School of Bioengineering, Dalian University of Technology, Dalian, China
    Competing interests
    No competing interests declared.
  2. Meisuo Liu

    School of Bioengineering, Dalian University of Technology, Dalian, China
    Competing interests
    No competing interests declared.
  3. Xibao Tian

    School of Bioengineering, Dalian University of Technology, Dalian, China
    Competing interests
    No competing interests declared.
  4. Haina Wang

    School of Bioengineering, Dalian University of Technology, Dalian, China
    Competing interests
    No competing interests declared.
  5. Jiujiao Gao

    School of Bioengineering, Dalian University of Technology, Dalian, China
    Competing interests
    No competing interests declared.
  6. Hanrui Li

    School of Bioengineering, Dalian University of Technology, Dalian, China
    Competing interests
    No competing interests declared.
  7. Zhehuan Zhao

    School of Software, Dalian University of Technology, Dalian, China
    Competing interests
    No competing interests declared.
  8. Yu Liu

    School of Software, Dalian University of Technology, Dalian, China
    Competing interests
    No competing interests declared.
  9. Caigang Liu

    Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
    For correspondence
    angel-s205@163.com
    Competing interests
    Caigang Liu, Senior editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2083-235X
  10. Xuan Chen

    School of Bioengineering, Dalian University of Technology, Dalian, China
    Competing interests
    No competing interests declared.
  11. Yongliang Yang

    School of Bioengineering, Dalian University of Technology, Dalian, China
    For correspondence
    everbright99@foxmail.com
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0449-0599

Funding

National Natural Science Foundation of China (81874301)

  • He Liu
  • Meisuo Liu
  • Xibao Tian
  • Haina Wang
  • Jiujiao Gao
  • Hanrui Li
  • Zhehuan Zhao
  • Yu Liu
  • Xuan Chen
  • Yongliang Yang

National Natural Science Foundation of China (U20A20381,82373063)

  • Caigang Liu

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Animal studies in the present work have been conducted in accordance with the ethical standards and the Declaration of Helsinki. The investigation has been approved by the Research Ethics Committee (REC) of Dalian University of Technology (approval number: 2018-023).

Human subjects: The Research Ethics Committee (REC) of Dalian University of Technology approved conduct of ex vivo assays with donated human cells (approval number: 2018-023). Normal human peripheral blood mononuclear cells (PBMCs) were obtained from blood samples collected from healthy volunteers. Approval was obtained from The Second Affiliated Hospital of Dalian Medical University institutional review board for these studies.

Copyright

© 2023, Liu et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 561
    views
  • 96
    downloads
  • 3
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. He Liu
  2. Meisuo Liu
  3. Xibao Tian
  4. Haina Wang
  5. Jiujiao Gao
  6. Hanrui Li
  7. Zhehuan Zhao
  8. Yu Liu
  9. Caigang Liu
  10. Xuan Chen
  11. Yongliang Yang
(2023)
Discovery and biological evaluation of a potent small molecule CRM1 inhibitor for its selective ablation of extranodal NK/T cell lymphoma
eLife 12:e80625.
https://doi.org/10.7554/eLife.80625

Share this article

https://doi.org/10.7554/eLife.80625

Further reading

    1. Cancer Biology
    2. Cell Biology
    Maojin Tian, Le Yang ... Peiqing Zhao
    Research Article

    TIPE (TNFAIP8) has been identified as an oncogene and participates in tumor biology. However, how its role in the metabolism of tumor cells during melanoma development remains unclear. Here, we demonstrated that TIPE promoted glycolysis by interacting with pyruvate kinase M2 (PKM2) in melanoma. We found that TIPE-induced PKM2 dimerization, thereby facilitating its translocation from the cytoplasm to the nucleus. TIPE-mediated PKM2 dimerization consequently promoted HIF-1α activation and glycolysis, which contributed to melanoma progression and increased its stemness features. Notably, TIPE specifically phosphorylated PKM2 at Ser 37 in an extracellular signal-regulated kinase (ERK)-dependent manner. Consistently, the expression of TIPE was positively correlated with the levels of PKM2 Ser37 phosphorylation and cancer stem cell (CSC) markers in melanoma tissues from clinical samples and tumor bearing mice. In summary, our findings indicate that the TIPE/PKM2/HIF-1α signaling pathway plays a pivotal role in promoting CSC properties by facilitating the glycolysis, which would provide a promising therapeutic target for melanoma intervention.

    1. Cancer Biology
    2. Chromosomes and Gene Expression
    Ananda Kishore Mukherjee, Subhajit Dutta ... Shantanu Chowdhury
    Research Article

    Telomeres are crucial for cancer progression. Immune signalling in the tumour microenvironment has been shown to be very important in cancer prognosis. However, the mechanisms by which telomeres might affect tumour immune response remain poorly understood. Here, we observed that interleukin-1 signalling is telomere-length dependent in cancer cells. Mechanistically, non-telomeric TRF2 (telomeric repeat binding factor 2) binding at the IL-1-receptor type-1 (IL1R1) promoter was found to be affected by telomere length. Enhanced TRF2 binding at the IL1R1 promoter in cells with short telomeres directly recruited the histone-acetyl-transferase (HAT) p300, and consequent H3K27 acetylation activated IL1R1. This altered NF-kappa B signalling and affected downstream cytokines like IL6, IL8, and TNF. Further, IL1R1 expression was telomere-sensitive in triple-negative breast cancer (TNBC) clinical samples. Infiltration of tumour-associated macrophages (TAM) was also sensitive to the length of tumour cell telomeres and highly correlated with IL1R1 expression. The use of both IL1 Receptor antagonist (IL1RA) and IL1R1 targeting ligands could abrogate M2 macrophage infiltration in TNBC tumour organoids. In summary, using TNBC cancer tissue (>90 patients), tumour-derived organoids, cancer cells, and xenograft tumours with either long or short telomeres, we uncovered a heretofore undeciphered function of telomeres in modulating IL1 signalling and tumour immunity.